Healthcare [ 10/13 ] | Biotechnology [ 90/160 ]
NASDAQ | Common Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 2, 24 | -0.1 Increased by 0% | -0.11 Increased by +9.09% |
| Feb 29, 24 | -0.12 Increased by +14.29% | -0.12 |
| Nov 7, 23 | -0.12 Increased by 0% | -0.11 Decreased by -9.09% |
| Aug 3, 23 | -0.1 Increased by 0% | -0.11 Increased by +9.09% |
| May 4, 23 | -0.1 Increased by +9.09% | -0.14 Increased by +28.57% |
| Mar 2, 23 | -0.14 Increased by +6.67% | -0.13 Decreased by -7.69% |
| Nov 9, 22 | -0.12 Increased by +50% | -0.13 Increased by +7.69% |
| Aug 4, 22 | -0.1 Increased by +56.52% | -0.13 Increased by +23.08% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 23 | 2.15 M Decreased by -65.65% | -19.31 M Increased by +15.71% | Decreased by -900.33% Decreased by -145.41% |
| Sep 30, 23 | 4.66 M Decreased by -21.74% | -20.1 M Decreased by -16.05% | Decreased by -431.6% Decreased by -48.29% |
| Jun 30, 23 | 4.65 M Decreased by -67.34% | -17.09 M Decreased by -19.75% | Decreased by -367.53% Decreased by -266.66% |
| Mar 31, 23 | 6.69 M Decreased by -46.85% | -15.46 M Increased by +1.92% | Decreased by -231.24% Decreased by -84.54% |
| Dec 31, 22 | 6.25 M Increased by +94.79% | -22.91 M Decreased by -7.46% | Decreased by -366.87% Increased by +44.83% |
| Sep 30, 22 | 5.95 M Increased by +78.2% | -17.32 M Increased by +9.58% | Decreased by -291.05% Increased by +49.26% |
| Jun 30, 22 | 14.24 M Increased by +511.46% | -14.28 M Increased by +26.37% | Decreased by -100.24% Increased by +87.96% |
| Mar 31, 22 | 12.58 M Increased by +495.41% | -15.77 M Increased by +3.76% | Decreased by -125.31% Increased by +83.84% |
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.